Table 3.

The prevalence of use (%) of medications for urological conditions by healthcare system factors among 5503 men and women in the BACH Survey

	Men using				Women using
Factor	UI/OAB druga	PBlS drugb	LUTS/BPH drugc	ED drugd	UI/OAB druga	PBlS drugb
Healthcare system factors
Health insurance
Private	0.53	0.40	3.53	3.33	1.69	1.08
Public	0.31	2.49	5.57	1.47	2.03	2.96
None	0.84	0.51	0.98	0.74	0.67	1.27
P	0.624	0.070	< 0.001	0.062	0.125	0.106
Regular care
yes	0.70	0.94	4.14	2.57	1.75	1.76
no	0.00	0.30	1.46	2.75	0.96	0.00
P	0.012	0.083	0.008	0.918	0.436	< 0.001
N healthcare provider visits in last year
0	0.00	0.32	0.00	0.00	0.00	0.00
1–4	0.12	0.34	2.78	2.11	0.76	0.66
5–9	0.34	1.43	5.08	3.80	2.88	1.59
≥10	1.81	1.46	5.39	3.86	2.36	3.41
P	0.040	0.263	< 0.001	< 0.001	< 0.001	< 0.001
When did you last see a healthcare provider?
< 6 months	0.75	1.08	4.82	3.46	1.96	1.98
6–12 months	0.07	0.00	0.95	1.30	0.53	0.00
1–2 years	0.00	0.00	0.00	0.00	0.00	0.00
2–5 years	0.00	0.00	0.00	0.00	0.00	0.00
≥5 years	0.00	1.55	0.00	0.00	0.00	0.00
P	0.154	0.025	< 0.001	< 0.001	< 0.001	< 0.001
Reported trouble paying for healthcare/medications
Yes	0.77	0.37	2.74	2.83	1.68	2.99
No	0.49	0.88	3.68	2.57	1.71	1.35
P	0.560	0.178	0.306	0.844	0.970	0.072

P values from overall chi-square test. Medications were:

^aoxybutynin, tolterodine tartrate, propantheline bromide, hyoscyamine sulphate, and flavoxate hydrochloride

^bpentosan polysulphate and amitriptyline

^calfuzosin, doxazosin, tamsulosin, terazosin, and finasteride (no participant took dutasteride)

^dsildenafil, tadalafil, alprostadil, vardenafil, papaverine.